NCT01691365

Brief Summary

Substantial evidence shows that diets incorporating antioxidants and B-group vitamins can offer significant protection against infections and cardiovascular disease (CVD) especially in diabetic patients. The proposed study will determine whether improvements in antioxidants and B-group vitamins in diabetic patients who are known to have a high risk of CVD will lead to a clinical benefit

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for phase_4 diabetes

Timeline
Completed

Started Sep 2008

Typical duration for phase_4 diabetes

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2011

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

September 11, 2012

Completed
13 days until next milestone

First Posted

Study publicly available on registry

September 24, 2012

Completed
Last Updated

September 24, 2012

Status Verified

September 1, 2012

Enrollment Period

1.2 years

First QC Date

September 11, 2012

Last Update Submit

September 19, 2012

Conditions

Keywords

AntioxidantvitaminsDiet

Outcome Measures

Primary Outcomes (2)

  • Inflammation

    3 months

  • Oxidative damage

    3 months

Secondary Outcomes (1)

  • Antioxidant status

    3 months

Other Outcomes (1)

  • Infections

    12 months

Study Arms (2)

vitamins pills

ACTIVE COMPARATOR

antioxidant and B vitamins vitamins vitamin \--------------------------------------------------------------------------------

Dietary Supplement: vitamins

pills

PLACEBO COMPARATOR

MICROCRYSTALLINE CELLULOSE

Drug: Placebo

Interventions

vitaminsDIETARY_SUPPLEMENT

a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days

Also known as: Antioxidants, B vitamins
vitamins pills

Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)

pills

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 Diabetes mellitus

You may not qualify if:

  • severe chronic clinical or psychiatric disease,
  • participating in other intervention trials,
  • on dietary supplements and
  • those unable to give an informed written consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Gariballa S, Alkaabi J, Yasin J, Al Essa A. Total adiponectin in overweight and obese subjects and its response to visceral fat loss. BMC Endocr Disord. 2019 Jun 3;19(1):55. doi: 10.1186/s12902-019-0386-z.

MeSH Terms

Conditions

Diabetes MellitusObesity

Interventions

VitaminsAntioxidantsVitamin B Complex

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

MicronutrientsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesNutrientsFoodDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesBiological FactorsMolecular Mechanisms of Pharmacological ActionProtective AgentsSpecialty Uses of Chemicals

Study Officials

  • Salah Gariballa, MD

    United Arab Emirates University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 11, 2012

First Posted

September 24, 2012

Study Start

September 1, 2008

Primary Completion

December 1, 2009

Study Completion

June 1, 2011

Last Updated

September 24, 2012

Record last verified: 2012-09